(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 June 2021 (10.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/113739 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *A61P 37/06* (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:
PCT/US2020/063452

(22) International Filing Date:
04 December 2020 (04.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/944,082 05 December 2019 (05.12.2019) US

(72) Inventors; and
(71) Applicants: **BALLET, Thomas** [FR/US]; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, NJ 08807 (US). **BANGARI, Kiran** [—/US]; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, NJ 08807 (US). **CHARI, Ravi** [—/US]; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, NJ 08807 (US). **HUILLE, Sylvain** [FR/FR]; c/o Sanofi, 54 rue La Boétie, 75008 Paris (FR). **PEREZ-RAMIREZ, Bernardo** [US/US]; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, NJ 08807 (US). **VASCO, Filipe** [—/US]; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, NJ 08807 (US).

(74) Agent: **VELEMA, James, H.**; Lathrop GPM LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2021/113739 A1

(54) **Title:** FORMULATIONS OF ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATION

(57) **Abstract:** Provided are formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof. The formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa·s, and the pH of the solution is 5.9 to 7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations will find use in treating $CD38^+$ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.